

Vivos Therapeutics, Inc. (VVOS)

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001716166

Vivos Therapeutics, Inc. VIVOS; healthcare	
Grade	D A B C D E fourth fifth of 371 graded peers percentile 77.0; sampling error 2.5 points; lower is stronger
Rank	286 of 371
Profitability	B/C percentile 39.2
Solvency	D/E percentile 79.3
Growth and financing	C percentile 56.4
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$25.2M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	dilution, short runway, late filer not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Apr 15, 2026 177 days before the rescans; latest periodic filing 10-Q received Aug 14, 2026
Last close	\$0.15 2026-10-08; market equity \$3.0M
Price used in grade	None



D, the sloth
fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: E from Apr 21, 2024, E from Apr 21, 2025, D/E from Apr 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Apr 15, 2026

are a revenue stage medical technology and healthcare services company that features a comprehensive suite of proprietary oral appliances and therapeutic treatments. Our products non-surgically treat certain maxillofacial and developmental abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders such as mild to severe obstructive sleep apnea (known as OSA) and snoring in adults. We call the use of our appliances coupled with specific therapeutic treatment protocols The Vivos

Method.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 39.2						
Gross profitability		41.9%	32.2%	29.6	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(29.2%)	(6.6%)	14.9	811	2025-12-31
Gross margin stability, five years		5.6 pts	2.8 pts	73.1	243	2025-12-31
Solvency, sleeve percentile 79.3						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(25.19)	(0.31)	77.5	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		(14.21x)	(4.51x)	63.7	81	2025-12-31
Current ratio		0.24x	2.96x	96.8	839	2025-12-31
Growth and financing, sleeve percentile 56.4						
Revenue growth, three-year compound		2.9%	10.0%	64.0	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		22.4%	2.1%	19.3	704	2025-12-31
Net share issuance, one year		129.0%	2.5%	85.8	634	2026-04-15


Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 129.0%
Short runway	cash runway is 1.2 months
Late filer	found 4 NT 10-K/Q filings in the last eight quarters

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
281	Standard Biotoools Inc. (LAB)	75.7	D	late filer, fortress balance sheet
282	Abeona Therapeutics Inc. (ABEO)	75.9	D	fortress balance sheet
283	Cytosorbents Corp. (CTSO)	76.2	D	short runway, fortress balance sheet
284	Tilray Brands, Inc. (TLRY)	76.5	D	fortress balance sheet
285	Baxter International Inc. (BAX)	76.8	D	
286	Vivos Therapeutics, Inc. (VVOS) <	77.0	D	dilution, short runway, late filer
287	Quest Diagnostics Inc. (DGX)	77.3	D	
288	biote Corp. (BTMD)	77.6	D/E	
289	Protalix BioTherapeutics, Inc. (PLX)	77.8	D/E	
290	Femasys Inc. (FEMY)	78.1	D/E	dilution, short runway
291	X4 Pharmaceuticals, Inc. (XFOR)	78.4	D/E	dilution, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(93.7%)	8.0%	1
Distance from 52-week high	(95.3%)	(31.4%)	2
EBIT to enterprise value	(1,095.7%)	(1.5%)	1
Free cash flow yield	(585.3%)	(1.0%)	1
Book value to price	(1.27)	0.28	1
Sales to price	5.80	0.31	98
Composite equity issuance, five years	331.8%	20.3%	96
Relative strength against the sector, log excess return	(2.97)	(0.14)	1

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 3 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass

Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$1.8M
Operating cash flow, four quarters	-\$17.1M
Months of runway	1.2
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$199,100

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$10.5M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
2	assets	us-gaap:Assets	\$25.2M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
3	net income	us-gaap:NetIncomeLoss	-\$21.2M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$15.3M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
5	assets	us-gaap:Assets	\$15.3M	2024-12-31	2026-04-15	10-K	0001493152-26-016854
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$17.4M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
7	gross profit	us-gaap:GrossProfit	\$9.0M	2024-12-31	2026-04-15	10-K	0001493152-26-016854
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$15.0M	2024-12-31	2026-04-15	10-K	0001493152-26-016854
9	gross profit	us-gaap:GrossProfit	\$8.3M	2023-12-31	2025-03-31	10-K	0001641172-25-001750
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$13.8M	2023-12-31	2025-03-31	10-K	0001641172-25-001750
11	gross profit	us-gaap:GrossProfit	\$10.0M	2022-12-31	2024-07-30	10-K/A	0001493152-24-029491
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$16.0M	2022-12-31	2024-07-30	10-K/A	0001493152-24-029491
13	gross profit	us-gaap:GrossProfit	\$12.6M	2021-12-31	2023-03-30	10-K	0001493152-23-009765
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$16.9M	2021-12-31	2023-03-30	10-K	0001493152-23-009765
15	current assets	us-gaap:AssetsCurrent	\$4.4M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
16	current liabilities	us-gaap:LiabilitiesCurrent	\$18.1M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$125.4M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
18	operating income	us-gaap:OperatingIncomeLoss	-\$19.9M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
19	book equity	us-gaap:StockholdersEquity	-\$1.5M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
20	liabilities	us-gaap:Liabilities	\$26.7M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
21	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$2.9M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
22	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$2.0M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
23	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$1.3M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
24	interest expense	us-gaap:InterestExpense	\$1.4M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.3M	2025-12-31	2026-04-15	10-K	0001493152-26-016854
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$12.7M	2024-12-31	2026-04-15	10-K	0001493152-26-016854
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$568,000	2024-12-31	2026-04-15	10-K	0001493152-26-016854
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$11.9M	2023-12-31	2025-03-31	10-K	0001641172-25-001750
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$803,000	2023-12-31	2025-03-31	10-K	0001641172-25-001750
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$19.6M	2022-12-31	2024-07-30	10-K/A	0001493152-24-029491
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$924,000	2022-12-31	2024-07-30	10-K/A	0001493152-24-029491
32	assets	us-gaap:Assets	\$10.7M	2023-12-31	2025-03-31	10-K	0001641172-25-001750
33	assets	us-gaap:Assets	\$13.7M	2022-12-31	2024-07-30	10-K/A	0001493152-24-029491
34	shares outstanding	dei:EntityCommonStockSharesOutstanding	13,486,006	2026-04-15	2026-04-15	10-K	0001493152-26-016854
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	5,889,520	2025-03-31	2025-03-31	10-K	0001641172-25-001750